A tissue-engineered subcutaneous pancreatic cancer model for antitumor drug evaluation

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 1167-1176

  He, Qingyi ^b   Wang, Xiaohui ^c   Zhang, Xing ^d   Han, Huifang ^d   Han, Baosan ^e   Xu, Jianzhong ^b   Tang, Kanglai ^b   Fu, Zhiren ^a   Yin, Hao ^a,d  

^a Department of Surgery   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c Department of General Surgery   (China)

^d UNIVERSITY OF CHICAGO   (United States)

^e XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Cancer stem cell; Electrospun scaffold; Gemcitabine; Oxaliplatin; Pancreatic cancer

Indexed keywords

CD24 ANTIGEN; GEMCITABINE; HERMES ANTIGEN; OXALIPLATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STEM CELL; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; PANCREAS CANCER; STRUCTURE ANALYSIS; TISSUE ENGINEERING;

CANCER STEM CELL; ELECTROSPUN SCAFFOLD; GEMCITABINE; OXALIPLATIN; PANCREATIC CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL SURVIVAL; DEOXYCYTIDINE; FEMALE; FLOW CYTOMETRY; HUMANS; MICE, NUDE; NANOFIBERS; NANOTECHNOLOGY; NEOPLASMS, EXPERIMENTAL; NEOPLASTIC STEM CELLS; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS; TISSUE SCAFFOLDS; TUMOR CELLS, CULTURED;

EID: 84875310776     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S42464     Document Type: Article

References (37)

1. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19): 1817-1825.
2. Kanai M, Yoshimura K, Asada M, et al. A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Cancer Chemother Pharmacol. 2011;68(1):157-164.
3. Oh SY, Kim HJ, Kim TH, et al. Pilot study of irinotecan/oxalipaltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil-refractory pancreatic cancer. Invest New Drugs. 2010; 28(3):343-349.
4. Rothenberg ML, Moore MJ, Cripps MC, et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol. 1996;7(4):347-353.
5. Cheon DJ, Orsulic S. Mouse models of cancer. Annu Rev Pathol. 2011;6:95-119.
6. Garber K. Realistic rodents? Debate grows over new mouse models of cancer. J Natl Cancer Inst. 2006;98(17):1176-1178.
7. Hoffman RM. Orthotopic is orthodox: why are orthotopic-transplant metastatic models different from all other models? J Cell Biochem. 1994;56(1):1-3.
8. Killion JJ, Radinsky R, Fidler IJ. Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metastasis Rev. 1998;17(3):279-284.
9. Richmond A, Su Y. Mouse xenograft models vs GEM models for human cancer therapeutics. Dis Model Mech. 2008;1(2-3):78-82.
10. Dorado J, Lonardo E, Miranda-Lorenzo I, Heeschen C. Pancreatic cancer stem cells: new insights and perspectives. J Gastroenterol. 2011;46(8):966-973.
11. Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007;1(3):313-323.
12. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med. 2006;355(12):1253-1261.
13. Lee CJ, Dosch J, Simeone DM. Pancreatic cancer stem cells. J Clin Oncol. 2008;26(17):2806-2812.
14. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414(6859):105-111.
15. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008;8(10):755-768.
16. Hutmacher DW. Biomaterials offer cancer research the third dimension. Nat Mater. 2010;9(2):90-93.
17. Hutmacher DW, Horch RE, Loessner D, et al. Translating tissue engineering technology platforms into cancer research. J Cell Mol Med. 2009;13(8A):1417-1427.
18. Kim JB. Three-dimensional tissue culture models in cancer biology. Semin Cancer Biol. 2005;15(5):365-377.
19. Lee J, Cuddihy MJ, Kotov NA. Three-dimensional cell culture matrices: state of the art. Tissue Eng Part B Rev. 2008;14(1):61-86.
20. Lutolf MP, Hubbell JA. Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering. Nat Biotechnol. 2005;23(1):47-55.
21. Thomas V, Zhang X, Catledge SA, Vohra YK. Functionally graded electrospun scaffolds with tunable mechanical properties for vascular tissue regeneration. Biomed Mater. 2007;2(4):224-232.
22. Thomas V, Zhang X, Vohra YK. A biomimetic tubular scaffold with spatially designed nanofibers of protein/PDS bio-blends. Biotechnol Bioeng. 2009;104(5):1025-1033.
23. Zhang X, Thomas V, Vohra YK. In vitro biodegradation of designed tubular scaffolds of electrospun protein/polyglyconate blend fibers. J Biomed Mater Res A. 2009;89(1):135-147.
24. Zhang X, Thomas V, Vohra YK. Two ply tubular scaffolds comprised of proteins/poliglecaprone/polycaprolactone fibers. J Mater Sci. 2010;21(2):541-549.
25. Zhang X, Thomas V, Xu Y, Bellis SL, Vohra YK. An in vitro regenerated functional human endothelium on a nanofibrous electrospun scaffold. Biomaterials. 2010;31(15):4376-4381.
26. Zhang X, Xu Y, Thomas V, Bellis SL, Vohra YK. Engineering an antiplatelet adhesion layer on an electrospun scaffold using porcine endothelial progenitor cells. J Biomed Mater Res. 2011;97(2): 145-151.
27. Gaviraghi M, Tunici P, Valensin S, et al. Pancreatic cancer spheres are more than just aggregates of stem marker-positive cells. Biosci Rep. 2011;31(1):45-55.
28. Jimeno A, Feldmann G, Suarez-Gauthier A, et al. A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. Mol Cancer Ther. 2009;8(2):310-314.
29. Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005;23(15):3509-3516.
30. Dvir T, Timko BP, Kohane DS, Langer R. Nanotechnological strategies for engineering complex tissues. Nat Nanotechnol. 2011;6(1):13-22.
31. Balasundaram G, Webster TJ. An overview of nano-polymers for orthopedic applications. Macromol Biosci. 2007;7(5):635-642.
32. Weiler A, Hoffmann RF, Stahelin AC, Helling HJ, Sudkamp NP. Biodegradable implants in sports medicine: the biological base. Arthroscopy. 2000;16(3):305-321.
33. Fischbach C, Chen R, Matsumoto T, et al. Engineering tumors with 3D scaffolds. Nat Methods. 2007;4(10):855-860.
34. Hong SP, Wen J, Bang S, Park S, Song SY. CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. Int J Cancer. 2009;125(10):2323-2331.
35. Weber GF, Bronson RT, Ilagan J, Cantor H, Schmits R, Mak TW. Absence of the CD44 gene prevents sarcoma metastasis. Cancer Res. 2002;62(8):2281-2286.
36. Zhu J, He J, Liu Y, Simeone DM, Lubman DM. Identification of glycoprotein markers for pancreatic cancer CD24+CD44+ stem-like cells using nano-LC-MS/MS and tissue microarray. J Proteome Res. 2012;11(4):2272-2281.
37. Sergeant G, Vankelecom H, Gremeaux L, Topal B. Role of cancer stem cells in pancreatic ductal adenocarcinoma. Nat Rev Clin Oncol. 2009;6(10):580-586.